- Exchange: EN Brussels
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
ThromboGenics NV
+ Add to WatchlistTHR:BB
33.8550 EUR 0.1450 0.43%As of 11:35:05 ET on 05/24/2013.
Snapshot for ThromboGenics NV (THR)
| Open: | 34.1000 | Day's Range: | 33.6800 - 34.3000 | Volume: | 262,491 |
|---|---|---|---|---|---|
| Previous Close: | 34.0000 | 52wk Range: | 17.1000 - 47.8200 | 1-Yr Rtn: | +49.60% |
Key Statistics for THR
| Current P/E Ratio (ttm) | 38.8621 |
|---|---|
| Estimated P/E(12/2013) | 16.9219 |
| Relative P/E vs. BEL20 | 1.3651 |
| Earnings Per Share (EUR) (ttm) | 0.8700 |
| Est. EPS (EUR) (12/2013) | 1.9980 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 1,212.43 |
| Shares Outstanding (M) | 35.86 |
| 30 Day Average Volume | 187,183 |
| Price/Book (mrq) | 5.3256 |
| Price/Sale (ttm) | 14.9828 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/29/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for THR
Company Profile & Key Executives for THR
ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.
| Desire CollenChairman/Founder | Patrik De HaesCEO/Executive Director |
| Chris BuyseCFO/Executive Director/Secy | Koen KasChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
THR News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page